Table 1.
The ratio of animals with clinical signs and the mortality after different treatment
| Compound | Dose (mg/kg.bw) SLN/Tilmicosin |
Animal number (Male/Female) |
Animals with clinical sign/treated animals | Died animals/treated animals | ||
|---|---|---|---|---|---|---|
| Male | Female | Male | Female | |||
| Til-HCO-SLN | 5000/540 | 5/5 | 5/5 | 5/5 | 0/5 | 0/5 |
| Til-HCO-SLN* | 766/75 | 5/5 | 0/5ab | 0/5ab | 0/5ab | 0/5ab |
| HCO-SLN | 5000/0 | 5/5 | 5/5 | 5/5 | 0/5 | 0/5 |
| HCO-SLN* | 766/0 | 5/5 | 0/5ab | 0/5ab | 0/5ab | 0/5ab |
| Tilmicosin | -/540 | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 |
| Tilmicosin* | -/75 | 5/5 | 5/5a, 3/3b | 5/5a, 4/4b | 2/5a, 1/3b | 1/5a, 1/4b |
| Saline | -/- | 5/5 | 0/5 | 0/5 | 0/5 | 0/5 |
| Saline* | -/- | 5/5 | 0/5ab | 0/5ab | 0/5ab | 0/5ab |
* Animal treated twice on the first and 7th day: (a) after first injection; (b) after second injection.